ArticleTherapeutic advances in hematology2026
Endothelial dysfunction and cardiac damage indicators in patients with β-thalassemia major under iron-chelation therapy.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with β-thalassemia major remain at risk for endothelial dysfunction and cardiac injury due to iron overload, oxidative stress, and chronic inflammation, even with iron-chelation therapy. Assessing vascular and cardiac serum biomarkers provides a practical tool to understand disease mechanisms and guide management. Objectives: This study aims to identify reliable diagnostic markers for endothelial dysfunction in β-thalassemia major patients, a known risk factor for cardiovascular disease. Design: Case-control, cross-sectional study. Methods: Serum markers of endothelial dysfunction and cardiac damage, along with lipid profiles, were assessed. In addition, the expression of genes encoding enzymes related to cellular antioxidant defense and ferroptosis was evaluated. Results: Sixty transfusion-dependent β-thalassemia major patients on iron-chelation therapy and 20 healthy controls participated in the study. Significant differences among control, splenectomized, and non-splenectomized β-thalassemia groups were observed for erythrocyte sedimentation rate (ESR), high mobility group box 1 (HMGB-1), interleukin-10 (IL-10), interleukin-18, fibroblast growth factor 21 (FGF21), soluble suppression of tumorigenicity 2 (sST2), and soluble vascular cell adhesion molecule-1 (sVCAM-1), but not interleukin-23, interleukin-33, or calprotectin. Receiver operating characteristic (ROC) analysis showed AUCs of 0.991, 0.990, 0.848, and 0.831 for IL-10, ESR, sST2, and sVCAM-1, respectively ( Conclusion: β-thalassemia major patients exhibit significant endothelial and cardiac injury markers, altered lipid profiles, and selective upregulation of antioxidant and ferroptosis-related genes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.